Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice

Autor: Ziyin Wang, Egon J. Jacobus, David C. Stirling, Stefanie Krumm, Katie E. Flight, Robert F. Cunliffe, Jonathan Mottl, Charanjit Singh, Lucy G. Mosscrop, Leticia Aragão Santiago, Annette B. Vogel, Katalin Kariko, Ugur Sahin, Stephanie Erbar, John S. Tregoning

Publikováno v: Molecular Therapy: Nucleic Acids, Vol 34, Iss , Pp 102045- (2023)

The response to mRNA vaccines needs to be sufficient for immune cell activation and recruitment, but moderate enough to ensure efficacious antigen expression. The choice of the cap structure and use of N1-methylpseudouridine (m1Ψ) instead of uridine

Externí odkaz: https://doaj.org/article/41e7361041324d99b26eb39f9bd0fb8e

Ultra-compacted single self-amplifying RNA molecules as quintessential vaccines

Autor: Jorge Moreno Herrero, Theo Stahl, Stephanie Erbar, Konrad Maxeiner, Anne Schlegel, Tijana Bacic, Leide Cavalcanti, Martin Schroer, Dmitri Svergun, Ugur Sahin, Heinrich Haas

We introduce aqueous phases comprising single, highly compacted self-amplifying messenger RNA (saRNA) molecules, that are suitable for prophylactic and therapeutic application, specifically for vaccination against infectious diseases. The formulation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e41aac1836e3ebecb6a1c15f2a5e1696
https://doi.org/10.21203/rs.3.rs-2142761/v1

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Autor: Bernadette Jesionek, Charles Tan, Christoph Kröner, Jennifer Obregon, Stephanie Hein, Kathleen M. Brasky, Andreas Kuhn, Leyla Fischer, Guy Singh, Diana Schneider, Kathrin U. Jansen, Jane Fontenot, Seungil Han, Michal Gazi, Corinna Rosenbaum, Ingrid L. Scully, Pei Yong Shi, Parag Sahasrabudhe, Stefanie A. Krumm, Hanna Junginger, Camila R. Fontes-Garfias, Julia Schlereth, Bonny Gaby Lui, Mathias Vormehr, Andre P. Heinen, Alptekin Güler, Stephanie Fesser, Sarah C. Dany, Ellene H. Mashalidis, Danka Pavliakova, Shambhunath Choudhary, Mohan S. Maddur, Petra Adams-Quack, Yvonne Feuchter, Matthew C. Griffor, Ferdia Bates, Ramón de la Caridad Güimil Garcia, Tara Ciolino, Özlem Türeci, Stefan Schille, Kena A. Swanson, Kerstin C. Walzer, Alexander Muik, Jakob Loschko, Ayuko Ota-Setlik, Nicole L. Nedoma, Lena M. Kranz, Tompkins Kristin Rachael, Thorsten Klamp, Ugur Sahin, Ann Kathrin Wallisch, Warren Kalina, Olga Gonzalez, Fulvia Vascotto, Philip R. Dormitzer, Ye Che, Kendra J. Alfson, Ricardo Carrion, Thomas Ziegenhals, Shannan Hall-Ursone, Rani S. Sellers, Thomas Hiller, Isis Kanevsky, Matthew R. Gutman, Michael W. Pride, Stephanie Erbar, Bianca Sänger, Deepak Kaushal, Journey Cole, David Eisel, Andreas A.H. Su, Joshua A. Lees, Annette B. Vogel, Arianne Plaschke

Publikováno v: Nature

A safe and effective vaccine against COVID-19 is urgently needed in quantities that are sufficient to immunize large populations. Here we report the preclinical development of two vaccine candidates (BNT162b1 and BNT162b2) that contain nucleoside-mod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3903ab0fb32c26fb7ed5bc8fa70296ed
https://doi.org/10.1038/s41586-021-03275-y

BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2

Autor: Oezlem Tuereci, Arianne Plaschke, Tompkins Kristin Rachael, Andre P. Heinen, Joshua A. Lees, Stefan Schille, Kena A. Swanson, Deepak Kaushal, Kathrin U. Jansen, Corinna Rosenbaum, Danka Pavliakova, Ugur Sahin, Shannan Hall-Ursone, Rani S. Sellers, Journey Cole, Parag Sahasrabudhe, Stefanie A. Krumm, Ferdia Bates, Stephanie Erbar, Isis Kanevsky, Bianca Saenger, Michal Gazi, Annette B. Vogel, Kathleen M. Brasky, Matthew R. Gutman, Hanna Junginger, Sarah C. Dany, Nicole L. Nedoma, Lena M. Kranz, Camila R. Fontes-Garfias, Julia Schlereth, Shambhunath Choudhary, Andreas A.H. Su, Ramon de la Caridad Gueimil Garcia, Seungil Han, Thorsten Klamp, Ayuko Ota-Setlik, Bonny Gaby Lui, Michael W. Pride, Fulvia Vascotto, Ann-Kathrin Wallisch, Ingrid L. Scully, Stephanie Hein, David Eisel, Charles Tan, Pei Yong Shi, Mathias Vormehr, Philip R. Dormitzer, Olga Gonzalez, Kendra J. Alfson, Thomas Hiller, Bernadette Jesionek, Thomas Ziegenhals, Stephanie Fesser, Jennifer Obregon, Petra Adams-Quack, Matthew C. Griffor, Alptekin Gueler, Yvonne Feuchter, Alexander Muik, Jakob Loschko, Jane Fontenot, Christoph Kroener, Ricardo Carrion, Leyla Fischer, Warren Kalina, Andreas N. Kuhn, Ye Che, Guy Singh, Diana Schneider, Mohan S. Maddur, Kerstin C. Walzer, Tara Ciolino, Ellene H. Mashalidis

A safe and effective vaccine against COVID-19 is urgently needed in quantities sufficient to immunise large populations. We report the preclinical development of two BNT162b vaccine candidates, which contain lipid-nanoparticle (LNP) formulated nucleo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b00b93d3b666e0e3993b1b7ab468149
https://doi.org/10.1101/2020.12.11.421008

Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses

Autor: Tim Beissert, Ekaterina Kinnear, Lena Wicke, Mario Perkovic, Kerstin C. Reuter, David C. Busse, Annette B. Vogel, Laura Lambert, Heinrich Haas, Ugur Sahin, John S. Tregoning, Stephen T. Reece, Stephanie Erbar

Publikováno v: Molecular Therapy

New vaccine platforms are needed to address the time gap between pathogen emergence and vaccine licensure. RNA-based vaccines are an attractive candidate for this role: they are safe, are produced cell free, and can be rapidly generated in response t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a95b4a78cdecceaeec3cb623a0519c11
http://hdl.handle.net/10044/1/56396